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Introduction
The regulation of IFN-γ and type 2 cytokine production by T cells is important for development of allergy and acute responses to allergen, and for the development of interventions. Inhaled β-agonist therapy is the most common treatments for acute asthmatic attacks. The primary beneficial effect of β-agonists is the relaxation of airway smooth muscle to counter airway constriction induced by histamines, leukotrienes, and other contractile agents released upon allergen binding to mast-cell bound IgE. Based on various established and assumed PKAdependent, inhibitory effects on T cells [1] [2] [3] [4] , monocytic cells 5 , and airway smooth muscle 6 , it could be predicted that β-agonists, which are capable of activating PKA through the β 2 -adrenergic receptor (β 2 AR), should also provide anti-inflammatory effects in asthmatics.
However, several studies indicate that β-agonist therapy may actually worsen inflammation [7] [8] [9] [10] [11] .
Moreover, the β 2 AR has received extensive attention as a candidate gene for asthma [12] [13] [14] .
The endogenous circulating β-agonist epinephrine has been reported to influence T cell responses in heart failure patients, who typically have elevated levels of serum epinephrine.
Yndestad et al. reported that peripheral T cells, but not monocytes, from heart failure patients exhibit increased expression of chemokines, IFN-γ, IL-18, and TNF superfamily genes 15 . Gage et al. found that combined beta-blocker and angiotensin converting enzyme inhibitor therapy reduced TNF-α secreted by PBMC from heart failure patients, and lowered the ratio of IFN-γ to IL-10 production as well 16 . However, the mechanisms for the modulation of cytokine levels by beta-agonist are not known.
β-agonist activation of the β 2 AR has been reported to block TCR-mediated signaling to inhibit both cytokine production (IFN-γ and IL-2) and proliferation of T cells 17, 18 . Among the For personal use only. on . by guest www.bloodjournal.org From 4 most controversial aspects of β-agonist effects on T cells are its effects on type 2 T cells. Two studies report a β-agonist-mediated inhibition of IL-4 and IL-13 production in freshly isolated human T cells 19, 20 , whereas most reports, in various systems including primary and clonal populations and polyclonal lines of T cells in murine and human systems, claim that β-agonists do not directly affect type 2 T cells 17, 18, 21 . Thus, discrepancies in the literature exist regarding the responsiveness of type 2 T cells to β-agonists. Although two studies identified β 2 AR mRNA in "Th2-polarized" human T cell cultures 19, 20 , no studies to date have demonstrated direct effects of β-agonists on type 2 cells.
PGE 2 , another activator of PKA, has been shown to have protective effects on allergic inflammation 22 , reducing inflammation when exogenously provided to subjects 23 and potentiating inflammation when antagonized in an in vivo murine model 24 . PGE 2 inhibits cellular functions in many immune cells, suppressing IL-12 and TNF-α production by monocytic cells 25, 26 , cytotoxic potential of NK cells 27, 28 , and IFN-γ and IL-2 production by T cells 1, 20, [29] [30] [31] [32] .
The effects of PGE 2 on type 2 (IL-4 + ) T cells 1, 20, 30, 32, 33 and allergy 34, 35 are less clear and somewhat controversial. Our searches failed to locate reports regarding direct effects of PGE 2 on T cell-IL-13 production, despite the importance of IL-13 in atopic disorders 36, 37 .
Thus, although both β-agonists and PGE 2 signal through Gs-coupled receptors linked to PKA activation, studies to date suggest they have disparate effects on T cell cytokine production.
In the present study we dissect the mechanisms underlying differential regulation of IL-2, IL-13, and IFN-γ production by β-agonists and PGE 2 on acute stimulation of human PBL, both freshly isolated and cultured short-term. 
Materials and Methods
Isolation and short-term culture of PBL Venous blood was obtained from healthy volunteers, in accordance with a Wake Forest University Health Sciences Institutional Review Board approved protocol for these studies.
Informed consent was provided according to the Declaration of Helsinki. PBMC were isolated by standard density gradient centrifugation, and monocytes were removed by adherence to plastics to obtain freshly isolated PBL. For short-term cultures, PBL were cultured in RPMI-1640 media supplemented with 5% pooled human plasma. When indicated, PBL were cultured:
6-d with IL-2 (50 U/ml, Hoffman-La Roche) + IL-12-neutralizing mAb (0.5μg/ml, R&D Systems); or 14-d with IL-2 + anti-IL-12 mAb + PHA-P (0.5μg/ml, Sigma), CD28 mAb (2μg/ml, 9.3, ATCC). IL-4 (R&D Systems) was used 10ng/ml in indicated cultures. CD2
−/lo T cells were isolated and cultured as detailed in 38 . Additional reagents: isoproterenol (ISO), forskolin, dibutryl-cAMP (db-cAMP) from Sigma; bisindolylmaleimide I (Bis I), H89, PGE 2 , SB203580, and U0126 from Biomol; Rp-8-Bromo-2'-O-monobutryl-cAMPs (Rp-Br-MBcAMPs) and Rp-8-CPT-cAMP from Biolog /Axxora.
Analysis of VASP-Ser157 phosphorylation
Cells were stimulated as indicated, formalin-fixed, permeabilized with saponin buffer, and analyzed for vasodilator stimulated phosphoprotein (VASP)-phospho-Ser157 (FITC-labeled 5C6, NanoTools/Axxora; 2° detection with AlexaFluor (AL) 488-labeled goat-anti-mouse IgG, 
Analysis of cytokine production
Cells were stimulated either: 5-h with PMA (2nM, Sigma), Calcimycin (200ng/ml, A23187, Sigma), IL-2 (100U/ml), and monensin (5μg/ml, Sigma, to prevent secretion of cytokines); or 18-h with IL-2, CD28 mAb (2μg/ml), and monensin on CD3-coated well (5μg/ml OKT3, Figure 1B) . Although H89 is a potent and highly efficacious PKA inhibitor, interpretation of its effects is confounded by nonspecific actions, including those as a beta-adrenergic receptor antagonist 46 .
As an alternative approach, we examined the effects of Rp-Br-MB-cAMPs and
Rp-8-CPT-cAMPs, which preferentially inhibit activation of type I and type II PKA, respectively 11 43 . In combination, Rp-Br-MB-cAMPs and Rp-8-CPT-cAMPs almost completely inhibited ISOand PGE 2 -induced phosphorylation of VASP ( Figure 1D ).
Interestingly, stimulation of either the CD3 complex with PHA or protein kinase C (PKC)
with PMA also induced a significant albeit relatively weak phosphorylation of VASP, which was inhibited by H89 ( Figure 2A ). CD28 co-stimulation did not affect PHA-stimulated VASP phosphorylation (not shown). A low level of basal VASP phosphorylation was consistently detected by both immunoblotting ( Figure 1A ) and flow cytometry, and was reversible by H89
( Figure 2A ). The VASP phosphorylation induced by both PHA and PMA, as well as the basal level of VASP phosphorylation, was also prevented by Bis I, an inhibitor specific for PKC, indicating that activation of PKA can occur downstream of PKC activation in T cells ( Figure   2B ). PHA-and PMA-mediated activation of PKA did not result from arachidonate metabolism into prostaglandins, indicated by the lack of effect by the cyclooxygenase inhibitor indomethacin (not shown). Bis I did not inhibit, but rather enhanced PGE 2 -stimulated VASP phosphorylation, suggesting PKC activity serves to desensitize responsiveness to PGE 2 . Bis I pretreatment also enhanced β-agonist-induced VASP phosphorylation ( Figure 2C ). The desensitizing effects of PKC likely occurred at the receptor/G-protein locus, as Bis I did not affect VASP phosphorylation by db-cAMP, a direct activator of PKA, or by forskolin, a direct activator of adenylyl cyclase.
Induction of PKA activity in type 2 T cells
Simultaneous analysis of β-agonist-induced PKA activity and cytokine profile is complicated by the necessary, concomitant stimulation for cytokine production because: 1) several hours are 
Effects of β-agonist and PGE 2 on type 2 T cell activation
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To gain insight into the potential effects of ISO-and PGE 2 -stimulated PKA activity on type 2 T cell activation, we examined the effects of these agonists on expression of CD25 (IL-2Rα), a transient activation marker whose expression is upregulated upon CD3-mediated stimulation.
PKA can inhibit CD3-mediated signaling at its most upstream events by inhibiting activation of p56 lck via Csk-binding protein (Cbp) and C-terminal src kinase (Csk) 2, 3 . Only a small fraction of the major (CRTH2 − ) T cell population in freshly isolated PBL expressed CD25, whereas most CRTH2 + (type 2) T cells expressed CD25 at moderate levels ( Figure 4A 
Modulation of cytokine production by PKA-activating agonists
We next examined the effects of PGE 2 and ISO on expression of IL-13, IL-2, and IFN-γ in T cells ( Figure 5 ). 5G ).
To determine if the PKA-activating agonists can affect signaling important for cytokine production that occurs downstream of the well-characterized block in p56 lck activation, cells
were stimulated with PMA+Calcimycin to bypass the most upstream signaling events involved in CD3-mediated signaling ( Figure 5) . Surprisingly, under these conditions inhibition of IL-2 and IFN-γ production by PGE 2 and ISO remained significant, but the inhibition of IL-13 production was lost. Furthermore, PGE 2 , but not ISO (variable, with no mean effect), actually augmented PMA+Calcimycin-stimulated IL-13 production. Given that the cellular transport inhibitor monensin (present the entire time of stimulation) prevents release of proteins to the cell surface or extracellular medium, paracrine effects from non-type 2 cells to type 2 cells would not account for these results. Similar results were observed when cultures highly enriched for IL-13 + cells (CD2 −/lo T cells, see Figure 3C ) were used, further supporting a lack of contribution of paracrine effects from non-type 2 cells (not shown). CAY10399, a selective EP2 receptor agonist, similarly increased IL-13 production and inhibited IFN-γ and IL-2 production, whereas
For personal use only. on October 28, 2017. by guest www.bloodjournal.org From the selective EP1/EP3 receptors agonist 17-phenyl-trinor-PGE 2 did not, suggesting that the effects of PGE 2 are mediated mainly by the EP2 receptor (not shown). db-cAMP mimicked the effects of PGE 2 in enhancing PMA+Calcimycin-induced IL-13 production and attenuating IFN-γ and IL-2 production, implicating cAMP-dependent pathways for the effects of PGE 2 and ISO on cytokine production ( Figure 5C ). The same modulation of cytokine production by PGE 2 As noted above, a low level of PKA activation occurs within the context of CD3-stimulated cytokine production. To further explore the relevance of low levels of PKA activity on cytokine production, the concentration-dependent effects of PGE 2 , ISO, and db-cAMP on CD3-stimulated IL-13 production was assessed ( Figure 5D ). 100nM and 1 μM PGE 2 inhibited IL-13 production similarly, whereas 10nM PGE 2 did not have a significant effect. The lowest concentration of PGE 2 tested (1nM) enhanced CD3-stimulated IL-13 production in each experiment performed. For β-agonist, 100nM -10μM ISO inhibited IL-13 production, whereas at 10nM and 1nM ISO, CD3-stimulated IL-13 production was enhanced in each experiment performed. For db-cAMP, a 5nM concentration enhanced CD3-stimulated IL-13 production, suggesting that generation of relatively low levels of cAMP/PKA activity by PGE 2 and β-agonist enhance IL-13 production. Conversely, low concentrations of PGE 2 , ISO, and db-cAMP did not increase CD3-stimulated IL-2 or IFN-γ production (not shown). PMA+Calcimycin-stimulated IL-13 production, increased at saturating concentrations of PGE 2 and db-cAMP, was not further increased by submaximal concentrations of these agents (not shown). Collectively these data suggest low levels of PKA activity are permissive for CD3-stimulated IL-13 production, whereas past a critical threshold of PKA activity IL-13 production is inhibited.
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Modulation of MAPK and NF-κB signaling by PGE 2 and β-agonist As noted above, PGE 2 and ISO inhibited IFN-γ production and PGE 2 enhanced IL-13 production even when the upstream CD3-stimulated signaling events were bypassed by stimulation with PMA+Calcimycin. In an attempt to identify signaling elements altered under these conditions, the effects of PGE 2 and ISO on PMA-induced phosphorylation of the p38 MAPK, p42/44 MAPK (ERK), and NF-κB p65 were examined ( Figure 6 ). Both PGE 2 and ISO significantly inhibited PMA-stimulated phosphorylation of p38 MAPK (60±15% and 41±18%, respectively). PGE 2 similarly inhibited NF-κB phosphorylation (63±24), but inhibited p42/44 phosphorylation to a lesser extent (25±8). Inhibition of p42/44 and NF-κB p65 by PGE 2 was significantly greater than inhibition by ISO, which only minimally inhibited p42/44 and NF-κB p65 phosphorylation (6±10% and 11±11%, respectively).
To clarify the roles of p38 and p42/44 in PMA-stimulated cytokine production, cells were pretreated with SB203580 (a selective p38 inhibitor 51 ), U0126 (selective for MEK, the upstream activator of p42/44 52 ), or both ( Figure 7) . Inhibition of IL-13 production by either U0126 or SB203580 alone was minimal. However, the combination of both MAPK inhibitors decreased IL-13 production by 74±6%. IFN-γ production was inhibited similarly by U0126 and SB203580, either alone (59±22% and 74±5%, respectively) or in combination (85±3%). IL-2 production was inhibited by U0126 (51±7%), less so by SB203580 (17±19%), and the combination of inhibitors was only modestly more effective than was U0126 alone (75±22%).
Collectively, these data indicate that: 1) IL-13 production requires either p38 or p42/44 activation, but not necessarily both; 2) IL-2 production is largely dependent on p42/44; whereas
For personal use only. on October 28, 2017. by guest www.bloodjournal.org From 3) IFN-γ production requires activation of both p38 and p42/p44. Inhibition of p38 by either ISO or PGE 2 appears sufficient to strongly inhibit PMA-stimulated IFN-γ production. The failure of PGE 2 or ISO to inhibit IL-13 production can be explained by their inability to sufficiently inhibit p42/p44. Conversely, the strong inhibition of IL-2 production by PGE 2 and ISO may be mediated in part by inhibition of p38 and p42/p44, but likely involves inhibition of other signaling elements.
Discussion
In this study we demonstrate that type 2 T cells directly respond to β-agonist to activate PKA and inhibit CD3-stimulated IL-13 production. Although both β-agonist and PGE 2 signal through G S -coupled GPCRs to stimulate PKA activity, there were disparate effects of the two agents on T cell cytokine production. The inhibition of CD3-stimulated IFN-γ, IL-2, and IL-13 production by PGE 2 was greater than the inhibition by ISO in all cases. This lesser inhibitory effect of ISO was associated with a lower level of PKA activation. Interestingly, concentration-dependent responses for all agents tested suggested a biphasic effect of PKA activity on CD3-stimulated IL-13 production, and comparison of the regulation of CD3-versus PMA-stimulated IL-13 production suggests that PKA acts at both upstream and downstream signaling events that promote IL-13 but inhibit IFN-γ and IL-2 production.
The reports in the literature on the effects of β-agonists on T cell cytokine production provide conflicting results. β-agonists have been reported to inhibit CD3-stimulated IFN-γ but not IL-4 expression in human PBL, determined by RT-PCR 18 . Similar results were reported for antigen-stimulated murine T cell clones, associated with detection of β 2 ARs on type 1 but not type 2 clones 17 . However, others have shown that β-agonists inhibit CD3-stimulated IL-4, IL-5, and IFN-γ production in freshly isolated human PBL, but not in "Th2-and Th-1 polarized" T cell cultures 20 . Goleva et al. reported that a combination of β-agonist with low-dose steroids inhibits PHA-stimulated proliferation and IL-13 production by human PBMC 19 . However, the contribution of non-T cells and to cytokine production could not be established because analyses
were not performed at the single-cell level. The disparity among these studies may reflect the agents ex vivo rather than in vivo is the ability to control the system and determine direct effects on T cells, at the single-cell level, rather than indirect effects modulated by other cell types responding to the agents. The approach employed in the current study takes into account all of these aspects described above by using freshly isolated human PBL and short-term cultured T cells, a full range of β-agonist concentrations, and determination of T cell cytokine production at the single cell level. Furthermore, direct comparisons to the effects of PGE 2 , another Gs-coupled receptor agonist, and db-cAMP, to specifically mimic elevated cAMP levels, were made for β-agonist-mediated modulation of cytokine production and associated signaling events. The results strongly refute the notion that type 2 T cells do not directly respond to β-agonist.
It had been previously reported that human type 2 T cells 19, 20 , but not murine Th2 clones 17 , express β 2 AR mRNA. However, functionally relevant levels of protein expression had not AT by phosphorylation of NF-AT by PKA 56 . In contrast, PKA may potentially promote transcription by releasing hematopoietic protein tyrosine phosphatase (HePTP) from p42/p44 and p38, allowing them to be more efficiently phosphorylated 57, 58 . There are conflicting reports on whether PKA enhances 59, 60 or inhibits 42,61 the transactivating capacity of NF-κB p65.
We demonstrate here that CD3-stimulated IL-13 production, like IFN-γ and IL-2 production, is inhibited by ISO and PGE 2 , though more effectively by PGE 2 . Inhibition of IL-13 production is less efficient than inhibition of IFN-γ and IL-2 production by ISO or PGE 2 . The inhibition of production of each of these cytokines is likely mediated by the PKA-Csk
For personal use only. on October 28, 2017. by guest www.bloodjournal.org From mechanism described above. However, other mechanisms may also contribute to further inhibit IFN-γ and IL-2 production. ISO and PGE 2 inhibited PMA+Calcimycin-stimulated IFN-γ and IL-2 production, suggesting that modulation of signals that can occur downstream of the p56 lck -Csk locus could further inhibit IFN-γ and IL-2 production. Such a mechanism is not expected for IL-13 because PGE 2 enhances PMA+Calcimycin-stimulated IL-13 production. Rather, modulation of downstream signaling by PGE 2 could potentially offset the PKA-Csk block in upstream signaling for IL-13 production.
PMA-stimulated IL-13 production is not inhibited by ISO and is actually enhanced by PGE 2 , even though IFN-γ and IL-2 production is inhibited. The inhibition of p38 activation by ISO or PGE 2 was not expected to inhibit IL-13 production because inhibition of both p38 and p42/p44 activity was shown to be required to significantly inhibit IL-13 production. Based on our understanding of transcriptional regulation of IL-4 62,63 , one potential mechanism for the enhanced IL-13 production by PGE 2 is increased phosphorylation of CREB by PKA to enhance transactivation with CREB-binding protein (CBP)/p300. Our preliminary studies suggest that PGE 2 , but not β-agonist, promotes significantly higher phospho-CREB levels than does PMA.
The inhibition of CD3-stimulated IL-13 production by β-agonist and PGE 2 is not only lost at low concentrations of agonist, but IL-13 production is actually increased. At these low concentrations of agonist, activation of PKA induced by PGE 2 and ISO appears insufficient to induce Csk-dependent inhibition of p56 lck . In the absence of inhibition by Csk, the downstream signaling events that promote IL-13 production may be affected in a manner similar to how PGE 2 affects PMA-stimulated IL-13 production, possibly by PKA-mediated CREB phosphorylation. Consistent with our findings, Ozegbe et al. recently reported a trend that lowdose PGE 2 enhances antigen-stimulated IL-5 production by mouse lymph node T cells 64 . In vivo, T cells are likely exposed to both wide range of levels of PGE 2 in a paracrine manner, depending on the intensity of local inflammation and the complement of infiltrating inflammatory cells.
The inhibition of PMA-stimulated IFN-γ production by PGE 2 and β-agonist can readily be accounted for by inhibition of p38 phosphorylation, originally described here, because IFN-γ production is dependent on p38 activation, as described here and by others (reviewed in 65 ).
Inhibition of NF-κB and p42/p44 activation likely is not involved because ISO minimally affected their activation. Such a mechanism is less certain for the inhibition of IL-2 production because PMA-stimulated IL-2 production was much less sensitive to inhibition of p38 activity.
Inhibition of NF-κB and p42/p44 activation is probably not involved for the same reasons described for inhibition of IFN-γ production. A potential mechanism for inhibition of IL-2 production is high levels of phospho-CREB. In anergic T cells (defined as being defective in proliferative responses), levels of activated CREB are elevated, leading to transcriptional inhibition and defective IL-2 production 66 . The PKA-dependence for the inhibition of p38 phosphorylation and IFN-γ and IL-2 production is currently under investigation.
We show that T cells have a basal level of PKA activity, and CD3-and PMA-mediated stimulation increases PKA activity by ~2 and ~3-fold, respectively, dependent on PKC. An association of elevated PKA activity and TCR-mediated activation with co-stimulation with IL-1β, dependent on PKC, had been previously reported 41, 67 . However, the role of basal or CD3-stimulated PKA activity in T cell activation for cytokine production remains controversial.
Several groups suggest that basal or CD3-stimulated PKA activity is not required or may attenuate cytokine production 1, 4 , but others suggest that some level of PKA activity is required for efficient T cell activation 68, 69 . We demonstrate for the first time that VASP is phosphorylated upon CD3-mediated stimulation, dependent on induced PKA activity.
Our findings underscore the importance of considering the complex effects of PKAactivating agonists used not only under experimental conditions, but also for therapeutics, as with β-agonist therapy for control of asthma. From the results in this study it is obvious that opposing results could be obtained for modulation of IL-13 production by PKA-activating agents depending on the concentration of agent used and the stimulus used to elicit cytokine production.
In terms of understanding the effects of endogenous or exogenously provided β-agonist or PGE 2 on disease, the effective concentrations of the agents in the environment of the responding cells need to be considered to predict the outcome on the cells. At high local concentrations as can occur with inhaled beta-agonist therapy 70, 71 , β-agonist could inhibit IL-13, IFN-γ, and IL-2 production by T cells responding to allergen, which could be beneficial for the asthmatic.
However, if the concentration is below the threshold for inhibition, IL-13 production by T cells responding to allergen (or other antigens, such as viral or bacterial) could be enhanced-a potentially detrimental outcome for the asthmatic. Establishing the prevalence of these concentration-dependent effects by PKA-activating agonists in other inflammatory cell types will be important in understanding how such agonists impact the inflammatory milieu in vivo. For personal use only. on October 28, 2017. by guest www.bloodjournal.org From
